ICUI · Icu Medical Inc/De · Insider Trading

The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.775 to $171.69, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.5 to $169.665, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.21 to $169.15, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.20 to $168.145, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2026.

All shares sold were sold at the exact price disclosed.

The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.69 to $173.765, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.77 to $174.08, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.57 to $171.495, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.625 to $172.6, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

All shares sold were sold at the exact price disclosed.

All shares sold were sold at the exact price disclosed.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.4808 to $182.5701, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.85 to $183.03, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.03 to $132.33, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

All shares sold were sold at the exact price disclosed.

These securities are Restricted Stock Units.

There is neither a purchase price nor an exercise price for Restricted Stock Units.

These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.

These securities are Restricted Stock Units.

There is neither a purchase price nor an exercise price for the Restricted Stock Units.

These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.

These securities are Restricted Stock Units.

These securities are Restricted Stock Units.

There is neither a purchase price nor an exercise price for Restricted Stock Units.

These securities are Restricted Stock Units.

There is neither a purchase price nor an exercise price for the Restricted Stock Units.

These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.

These securities are Restricted Stock Units.

There is neither a purchase price nor an exercise price for Restricted Stock Units.

These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.

These securities are Restricted Stock Units.

There is neither a purchase price nor an exercise price for the Restricted Stock Units.

These securities are Restricted Stock Units.

There is neither a purchase price nor an exercise price for the Restricted Stock Units.

These awards vest on the anniversary date of the date of the grant or the following annual stockholder meeting, whichever occurs first.

These securities are Restricted Stock Units.

There is neither a purchase price nor an exercise price for the Restricted Stock Units.

These awards vest on the anniversary date of the date of the grant or the following annual stockholder meeting, whichever occurs first.

These securities are Restricted Stock Units.

There is neither a purchase price nor an exercise price for the Restricted Stock Units.

These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.

These securities are Restricted Stock Units.

There is neither a purchase price nor an exercise price for the Restricted Stock Units.

These securities are Restricted Stock Units.

There is neither a purchase price nor an exercise price for the Restricted Stock Units.

These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.

These securities are Restricted Stock Units.

These securities are Restricted Stock Units.

There is neither a purchase price nor an exercise price for the Restricted Stock Units.

These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.

These securities are Restricted Stock Units.

There is neither a purchase price nor an exercise price for the Restricted Stock Units.

These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.

These securities are Restricted Stock Units.

There is neither a purchase price nor an exercise price for the Restricted Stock Units.

These awards vest on the anniversary of the date of the grant or the following stockholder meeting, whichever occurs first.

These securities are Restricted Stock Units.

There is neither a purchase price nor an exercise price for the Restricted Stock Units.

These awards vest on the anniversary of the date of the grant or the following stockholder meeting, whichever occurs first.

These securities are Restricted Stock Units.

All shares sold were at the exact price disclosed.

Represents transfer of shares of common stock by the reporting person pursuant to a domestic relations order. The reporting person no longer has a reportable beneficial interest in the shares transferred.

These Securities are Performance-based Restricted Stock Units (PRSU).

There is neither a purchase price nor an exercise price for the PRSUs.

Represents the settlement of performance stock units granted on 3/15/2023. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 117% of target, resulting in the acquisition of the shares reported herein.

These Securities are Performance-based Restricted Stock Units (PRSU).

Represents the settlement of performance stock units granted on 3/15/2023. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 117% of target, resulting in the acquisition of the shares reported herein.

These Securities are Performance-based Restricted Stock Units (PRSU).

Represents the settlement of performance stock units granted on 3/15/2023. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 117% of target, resulting in the acquisition of the shares reported herein.

These Securities are Performance-based Restricted Stock Units (PRSU).

There is neither a purchase price nor an exercise price for the PRSUs.

These PRSUs were granted on May 17, 2023. Vesting of these performance stock units are subject to the satisfaction of both performance-based conditions and time-based criteria. These PRSUs vest on March 15 of the first, second, and third year following the year of grant.

These Securities are Performance-based Restricted Stock Units (PRSU).

There is neither a purchase price nor an exercise price for the PRSUs.

Represents the settlement of performance stock units granted on 3/15/2023. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 117% of target, resulting in the acquisition of the shares reported herein.

These Securities are Performance-based Restricted Stock Units (PRSU).

Represents the settlement of performance stock units granted on 3/15/2023. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 117% of target, resulting in the acquisition of the shares reported herein.

These securities are Restricted Stock Units.

There is neither a purchase price nor an exercise price for the Restricted Stock Units.

These Securities are Performance-based Restricted Stock Units (PRSU).

These securities are Restricted Stock Units.

These securities are Restricted Stock Units.

These Securities are Performance-based Restricted Stock Units (PRSU).

There is neither a purchase price nor an exercise price for the PRSUs.

Represents the settlement of performance stock units granted on 3/15/2023. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 117% of target, resulting in the acquisition of the shares reported herein.